• Immunome, Inc. recently announced that the U.S. FDA accepted its New Drug Application for varegacestat, an oral, once‑daily gamma secretase inhibitor for adults with desmoid tumors, with a PDUFA target action date of April 28, 2027, based on Phase 3 RINGSIDE data showing a clinically meaningful 84% reduction in risk of progression or death.
• This milestone moves varegacestat into formal FDA review and places Immunome among a small group of companies advancing late‑stage therapies for desmoid tumors, a rare and difficult‑to‑treat condition.
• We’ll now examine how the FDA’s acceptance of varegacestat’s NDA and its strong Phase 3 results shape Immunome’s investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Immunome's Investment Narrative?

For Immunome, the big-picture belief is that varegacestat can anchor a rare-disease franchise while the ADC pipeline broadens the story beyond a single asset, even though the company still has minimal revenue and ongoing losses. The FDA’s acceptance of the varegacestat NDA is a meaningful short term catalyst shift: the drug is now in formal review with a clear PDUFA date, which tends to focus attention on regulatory milestones rather than early-stage pipeline progress. At the same time, the recent removal from several Russell indices, insider share sales and continued cash burn keep financing and dilution risk front and center. The stock’s strong 1-year run-up suggests a lot is already priced in, so how the market weighs NDA progress against funding needs may matter more from here.

However, one risk that has become more important after the NDA news may surprise some investors. Immunome's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value views from the Simply Wall St Community span roughly US$35 to US$185 per share, highlighting a wide gap in expectations. You are seeing that spread at the same time as varegacestat’s NDA moves into review, which sharpens the focus on Immunome’s funding runway and the possibility of further dilution if the path to meaningful revenue stretches out.

Explore 2 other fair value estimates on Immunome - why the stock might be worth over 7x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.